Evidence map›Paper›PMID 40426089›Full record

ArticleBMC infectious diseases2025

Escherichia coli causing bloodstream infections in Mexican paediatric patients: molecular typing, antimicrobial resistance, virulence factors, and clinical features.

Laura Belmont-Monroy, Jocelin Merida-Vieyra, Ruben Bautista-Hernandez, Josúe Adonis Mateo-Arreola, Agustín de Colsa-Ranero, Isabel Medina-Vera, Erik Emmanuel Jandete-Martinez, Alejandra Aquino-Andrade

Abstract read
In one paragraph

Article in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Laura Belmont-Monroy *Laboratory of Molecular Microbiology, Instituto Nacional de Pediatria, Mexico City, Mexico.
Jocelin Merida-Vieyra *Laboratory of Molecular Microbiology, Instituto Nacional de Pediatria, Mexico City, Mexico.
Ruben Bautista-HernandezLaboratory of Molecular Microbiology, Instituto Nacional de Pediatria, Mexico City, Mexico.
Josúe Adonis Mateo-ArreolaLaboratory of Molecular Microbiology, Instituto Nacional de Pediatria, Mexico City, Mexico.
Agustín de Colsa-RaneroDepartment of Pediatric Infectious Diseases, Instituto Nacional de Pediatria, Mexico City, Mexico.
Isabel Medina-VeraDepartment of Research Methodology, Instituto Nacional de Pediatria, Mexico City, Mexico.
Erik Emmanuel Jandete-MartinezLaboratory of Molecular Microbiology, Instituto Nacional de Pediatria, Mexico City, Mexico.
Alejandra Aquino-AndradeLaboratory of Molecular Microbiology, Instituto Nacional de Pediatria, Mexico City, Mexico. aaquinoa@pediatria.gob.mx.

Funding

Consejo Nacional de Humanidades, Ciencias y Tecnologías FOSISS 2012-1-18104Fiscal resource modality A and B Instituto Nacional de Pediatria 2013/066
6 · The paper itself

Abstract

backgroundEscherichia coli is one of the main pathogens causing bloodstream infections (BSIs) in paediatric patients. It is classified into pathogenic (B2, D and F) and commensal (A, B1 and C) phylogroups, with virulence mainly attributed to adhesins, toxins and iron acquisition systems. In recent years, the global spread of high-risk clones such as ST131 and ST405, often associated with extended-spectrum beta-lactamases (ESBLs), has contributed to increased resistance and limited treatment options. The BSI mortality rate in children varies from 14 to 21.6%. This study aimed to describe resistant mechanisms; virulence factors and clonal distribution of E. coli isolates that cause BSIs in children in Mexico and clinical features.

methodsThirty-eight ceftriaxone (CRO)-resistant E. coli isolates were included. Beta-lactamase and virulence genes were detected by PCR. Molecular typing included phylogroup determination, sequence types (ST), and pulsed-field gel electrophoresis (PFGE). Clinical information was acquired.

resultsCTX-M was the most frequently identified beta-lactamase (82%) and aac(6')-Ib-cr was present in 45%. Phylogroup distribution was A (21.1%), C (7.9%), D (28.9%), B2 (23.7%), and F (18.4%). The most common virulence factor was fimH (71%), while papC, sat and irp2 were significantly more frequently in the pathogenic phylogroups (P = 0.029, 0.011 and 0.006, respectively). PFGE identified 5 clusters, 20 non-related isolates and 4 non-typeable. Predominant clonal complexes (CC) were CC405 (23.7%) and CC131 (21.1%), with 82% of isolates belonging to high-risk clones. Survival rates differed significantly with moderate high-grade fever (P = 0.022). All patients who died had complications, compared to 34.8% of survivors (P < 0.0001). Mortality was higher in adolescents (53.3%), patients with leukaemia or lymphoma (40%), those with hospital-acquired infections (86.8%), those with an abdominal or pulmonary focus (33.3% each). No significant differences were found in of haematological parameters.

conclusionsBoth commensal and pathogenic E. coli strains cause BSIs in paediatric patients with underlying diseases. Resistance to 3GCs and 4GCs is mainly mediated by CTX-M, hence treatment with carbapenems was used. Infection-related deaths were more frequent in patients infected by pathogenic phylogroups, where papC, sat, and irp2 were more prevalent. High-risk clones were widely distributed among isolates.

Indexed as

BacteremiaDrug Resistance, BacterialEscherichia coliEscherichia coli InfectionsVirulence FactorsAdolescentAnti-Bacterial Agentsbeta-LactamasesChildChild, PreschoolElectrophoresis, Gel, Pulsed-FieldFemaleGenotypeHumansInfantInfant, NewbornAnti-Bacterial Agentsbeta-LactamasesVirulence FactorsBSIE. coliESBLExPECHigh-risk cloneMexicoPaediatric patientsPhylogenetic groupsVirulence factors

Identifiers

PMID40426089
PMCPMC12117857

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.